Purpose PIK3CA mutation and subsequent activation of the AKT pathway play an important
role in colorectal carcinogenesis. However, little is known about the prognostic role of …

Background: It has been reported that KRAS mutations (and to a lesser extent KRAS
mutations with the BRAF V600E mutation) negatively affect response to anti-epidermal …

Purpose: EGF receptor (EGFR) and HER2 positivity are considered to be negative
prognostic factors in gastric cancer. Biomarker analysis was conducted to evaluate the …

The epidermal growth factor receptor (EGFR) plays an important role in tumorigenesis and
tumor progression of colorectal cancer (CRC). As a result, the EGFR has evolved as a …

Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth
factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer …

Monoclonal antibodies targeting the Epidermal Growth Factor Receptor (EGFR), such as
cetuximab and panitumumab, have evolved to important therapeutic options in metastatic …

Background KRAS mutations occur in 35–45% of metastatic colorectal cancers (mCRC) and
preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab …

Triple-negative breast cancers represent a subset of breast cancers with a particularly
aggressive phenotype and poor clinical outcomes. Recent molecular profiling of these …

Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR)
monoclonal antibodies used as therapies for metastatic colorectal cancer patients. Intrinsic …

Background: Two groups of agents targeting either the vascular endothelial growth factor
(VEGF) receptor or the epidermal growth factor receptor (EGFR) have been added to the …